What is the appropriate treatment for hemolytic transfusion reactions?

Treatment of Hemolytic Transfusion Reactions

Immediately stop the transfusion, maintain IV access with normal saline, and initiate aggressive supportive care focused on preserving renal function and managing hemodynamic instability 1.

Immediate Actions

When a hemolytic transfusion reaction is suspected, the priority is rapid recognition and cessation of further incompatible blood exposure:

• Stop the transfusion immediately and keep the IV line open with normal saline
• Do not remove the IV catheter - maintain vascular access for treatment
• Notify the blood bank and ordering physician immediately
• Send appropriate diagnostic samples before instituting therapy 1

The clinical signs during anesthesia include hypotension, tachycardia, hemoglobinuria, and microvascular bleeding, though these may be masked or attributed to other causes in anesthetized patients 1. Monitor urine output and color, as well as peak airway pressure 1.

Supportive Management

Renal Protection (Primary Goal)

The cornerstone of treatment is preventing acute renal failure from hemoglobinuria:

• Aggressive IV fluid resuscitation to maintain urine output >100 mL/hour (or >1 mL/kg/hour)
• Maintain intravascular volume with crystalloid solutions
• Consider diuretics (furosemide) if adequate urine output is not achieved with fluids alone
• Alkalinize urine (sodium bicarbonate) to prevent hemoglobin precipitation in renal tubules - though this is based on physiologic rationale rather than strong evidence

Hemodynamic Support

• Vasopressor support if hypotension persists despite fluid resuscitation
• Treat shock aggressively with standard critical care protocols
• Monitor for and treat disseminated intravascular coagulation (DIC) if it develops

Advanced Therapies for Severe Reactions

Based on the most recent evidence, consider therapeutic plasma exchange (TPE) or red blood cell exchange within 24 hours for severe acute hemolytic reactions, particularly when there has been large volume mismatched transfusion and poor response to basic supportive measures 2, 3. The 2026 case report demonstrates successful outcomes when TPE is implemented early 2.

Red Blood Cell Exchange Indications

Implement RBC exchange within 5 hours if:

• Large volume ABO-incompatible transfusion occurred
• Clinical deterioration to shock despite supportive care
• Progressive DIC
• Worsening hemolysis parameters 3

This represents a shift from purely supportive care to more aggressive removal of incompatible cells and antibodies.

Delayed Hemolytic Transfusion Reactions (DHTR)

For delayed reactions, particularly in sickle cell disease patients with hyperhemolysis:

First-Line Treatment

• High-dose corticosteroids: methylprednisolone or prednisone 1-4 mg/kg/day 4
• Intravenous immunoglobulin (IVIg): 0.4-1 g/kg/day for 3-5 days (up to total 2 g/kg) 4
• Supportive erythropoiesis: erythropoietin with or without IV iron 4, 5

Second-Line Treatment for Refractory Cases

Eculizumab (complement C5 inhibitor) for patients continuing to deteriorate despite steroids and IVIg 4, 6, 5:

• Adult dose: 900-1200 mg weekly
• Requires meningococcal vaccination (MenACWY and MenB) and ciprofloxacin prophylaxis before administration
• Increasingly recognized as effective for complement-mediated hemolysis 6

Additional Considerations

• Rituximab may prevent additional alloantibody formation in patients requiring future transfusions 4
• Avoid further transfusion if possible during active DHTR, as it may exacerbate hemolysis 6, 7
• If life-threatening anemia requires transfusion, use extended antigen-matched RBCs (C/c, E/e, K, Jka/Jkb, Fya/Fyb, S/s) 4

Monitoring Requirements

Serial laboratory monitoring is essential:

• Hemoglobin/hematocrit
• Quantification of HbA and HbS fractions (in sickle cell patients)
• Reticulocyte count
• Bilirubin (total and direct)
• LDH
• Haptoglobin
• Urinalysis for hemoglobinuria
• Coagulation parameters (PT, PTT, fibrinogen, D-dimer)
• Renal function (creatinine, BUN)

Repeat measurements daily or more frequently if hemolysis is ongoing 2.

Critical Pitfalls to Avoid

1. Do not delay stopping the transfusion while waiting for laboratory confirmation
2. Do not give additional blood products without blood bank consultation and appropriate crossmatching
3. Do not use steroids and antihistamines indiscriminately for all transfusion reactions - distinguish between hemolytic, febrile, and allergic reactions 8
4. Do not transfuse during active DHTR with hyperhemolysis unless absolutely life-threatening, as it may worsen hemolysis 6, 7
5. Do not forget meningococcal prophylaxis before eculizumab administration 4

The evidence strongly supports early aggressive intervention for acute hemolytic reactions, with the 2026 literature 2 and recent case reports 3 demonstrating that therapeutic plasma exchange should be considered a standard adjunctive therapy rather than a last resort, particularly when implemented within the first 24 hours.